Article · Wikipedia archive · Last revised Jul 18, 2026

STAC-9

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.

Last revised
Jul 18, 2026
Read time
≈ 1 min
Length
166 w
Citations
3
Source
Wikipedia ↗
STAC-9
Identifiers
  • N-pyridin-4-yl-6-[3-(trifluoromethyl)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridine-1-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H15F3N4O
Molar mass384.362 g·mol−1
3D model (JSmol)
  • C1CN(C2=C1C=CC(=N2)C3=CC(=CC=C3)C(F)(F)F)C(=O)NC4=CC=NC=C4
  • InChI=1S/C20H15F3N4O/c21-20(22,23)15-3-1-2-14(12-15)17-5-4-13-8-11-27(18(13)26-17)19(28)25-16-6-9-24-10-7-16/h1-7,9-10,12H,8,11H2,(H,24,25,28)
  • Key:WFPOEJCACZIDSN-UHFFFAOYSA-N

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.123

See also

See also

References

References

  1. US 9556201, Ng PY, Blum C, Mcpherson L, Perni RB, Vu CB, Ahmed MM, Disch JS, "Bicyclic pyridines and analogs as sirtuin modulators.", published 4 October 2012, assigned to Sitris Pharmaceuticals and GlaxoSmithKline 
  2. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. (March 2013). "Evidence for a common mechanism of SIRT1 regulation by allosteric activators". Science. 339 (6124): 1216–9. Bibcode:2013Sci...339.1216H. doi:10.1126/science.1231097. PMC 3799917. PMID 23471411.
  3. Thevis M, Schänzer W (March 2016). "Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs". Rapid Communications in Mass Spectrometry. 30 (5): 635–51. Bibcode:2016RCMS...30..635T. doi:10.1002/rcm.7470. PMID 26842585. S2CID 206444739.